Ovasave

August 4, 2015August 4, 2015

MaSTherCell to Supply TxCell With Clinical Batches of Ovasave for Phase 2b Crohn’s Disease Study

IBD News, News

Cell therapy and regenerative medicine provider, Orgenesis, Inc., recently disclosed that its wholly-owned subsidiary, MaSTherCell, a contract development and manufacturing organization (CDMO), has signed an agreement of understanding with TxCell in ... Read more

July 29, 2015July 29, 2015

TxCell’s Ovasave for IBD Receives Fast Track Designation from US FDA

IBD News, News

TxCell SA, a biotechnology company that specializes in developing novel, patient-centered immunotherapies that utilize regulatory T-cells to address severe chronic inflammatory and autoimmune diseases, has just announced the US Food ... Read more

March 25, 2015March 25, 2015

TxCell Receives US Patent For Ovasave To Treat IBD

IBD News, News

A key patent was recently granted by the United States Patent and Trademark Office (USPTO) to TxCell SA for its lead product Ovasave® to address inflammatory bowel disease (IBD). The patent will protect Ovasave until 2030. TxCell SA ... Read more

January 28, 2015January 28, 2015

TxCell Granted €1.7M From Bpifrance to Develop Crohn’s Therapy

Crohn's Disease, News

Biotechnology company TxCell SA has been granted EUR 1.7 million ($1.9 million) from Bpifrance to support the development of the company’s lead product candidate Ovasave (ovalbumin-specific autologous Treg cells). TxCell is working on the ... Read more

January 5, 2015January 5, 2015

New Collaboration Formed to Further Develop IBD Drug Ovasave

IBD News, News

French biotechnology company TxCell SA, which specializes in the development of T-cell immunotherapy for severe chronic inflammatory and autoimmune diseases, recently published updates on the company’s efforts to develop its lead ... Read more

December 5, 2014December 5, 2014

TxCell Enrolls First Patient for Phase IIb Crohn’s Disease Study

News

TxCell SA, a biotechnology company specializing in developing novel immunotherapies for severe chronic inflammatory and autoimmune diseases, has just announced the enrollment and dosing of the first patient in the ... Read more